ArticleAging clinical and experimental research2025
Global, regional, and national burden of elderly myocarditis (1992-2021) and projections of future disease burden trends.
Article in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Global lifetime risk of developing myocarditis, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.BMJ open · 2026Article
- Global burden of myocarditis in adolescents and young adults, 1990-2019.BMC cardiovascular disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGeriatric myocarditis represents a significant public health concern, directly influencing overall health and potentially leading to various cardiac diseases. This study seeks to quantify the burden of geriatric myocarditis over three decades (1992-2021) and provide forecasts for future disease burden.
methodsData on geriatric myocarditis from 1992 to 2021 was obtained from the Global Burden of Disease study, offering insights into the incidence of the condition, categorized by gender. The Joinpoint regression model was utilized to identify shifts in epidemiological trends, while decomposition analysis helped identify the underlying factors contributing to these trends. To project future incidence, deaths and DALYs (Disability-Adjusted Life Years), the Norpred and Bayesian Age-Period-Cohort (BAPC) models were employed.
resultsIn 2021, the global ASIR (per 100,000) of elderly myocarditis was 47.57 (27.52-73.08), with 505,147 (292,319-774,561) cases. Age-standardized deaths(per 100,000) were 2.07 (1.55-2.51), totaling 20,718 (15,525-25,085) deaths, and age-standardized DALYs(per 100,000) were 29.77 (22.60-35.81), with 308,101 (234,226-370,674) DALYs. Greenland, Canada, and Austria had the highest ASIR(per 100,000), while Romania, Kazakhstan, and Croatia had the highest age-standardized deaths(per 100,000), and Romania, Kazakhstan, and Guyana had the highest age-standardized DALYs(per 100,000). Joinpoint Regression analysis revealed a recent upward trend in global incidence after a previous decline, consistent across genders and SDI regions. Deaths and DALYs showed declining trends globally, though male deaths recently increased. Decomposition analysis identified population growth and aging as key drivers of increased cases, deaths, and DALYs. Based on the nordpred model, by 2045, the global ASIR(per 100,000) is predicted to be 47.27, with 1,005,593 cases, age-standardized deaths(per 100,000) of 2.02, totaling 48,501 deaths, and age-standardized DALYs(per 100,000) of 26.21, with 595,694 DALYs. The BAPC model predicts a global ASIR(per 100,000) of 51.82, with 1,091,195 cases, age-standardized deaths(per 100,000) of 3.67, totaling 87,145 deaths, and age-standardized DALYs(per 100,000) of 49.09, with 1,084,738 DALYs.
conclusionAs of 2021, the ASIR(per 100,000) of myocarditis in the elderly population showed a decline compared to 1992; however, a recent upward trend has been identified. Considering ongoing population growth, the number of myocarditis cases among the elderly is anticipated to increase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.